Market Intelligence, Clinical Progress, and High-Purity Reagents for Autoimmune and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TNF Beta (LTA) drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TNF Beta (LTA) ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View LTA Products |
| Gene Delivery | TNF Beta (LTA) Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View LTA Products |
| Benchmark Ab | Anti-TNF Beta (LTA) (Sequence of Pateclizumab) Recombinant positive control. |
View LTA Products |
| Validator | TNF Beta (LTA) siRNA Set For knockdown verification. |
View LTA Products |
| Related Target A | LTB (Lymphotoxin Beta) Forms heterotrimers with LTA (LTA1B2) to mediate membrane-bound signaling. |
View LTB Products |
| Related Target B | TNF (TNF-alpha) Shares receptors TNFRSF1A and TNFRSF1B; critical for cross-reactivity counter-screening. |
View TNF Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Trimerization & Conformation Fidelity | HEK293 expressed recombinant LTA ensuring native glycosylation and correct homotrimeric folding. |
| Selectivity Counter-Screening | High-purity TNF-alpha and LTB homolog proteins strictly verified by mass spectrometry. |
| Lack of Controls | Recombinant Pateclizumab biosimilar available for assay standardization. |
| False Positives | Sequence-verified siRNA sets included for target-specific knockdown validation. |
Live TNF Beta (LTA) R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TNF Beta (LTA) therapeutics is intensifying, with major players shifting focus from traditional systemic cytokine inhibition to localized microenvironment modulation and dual-targeting bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting tertiary lymphoid structures (TLS) in oncology and chronic inflammatory conditions where LTA plays a structural role.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Genentech (Pateclizumab), Sanofi | Rheumatoid Arthritis, Inflammatory Bowel Disease | Blocking assay validation (Requires high-purity LTA homotrimer) |
| Decoy Receptor / Fusion Protein | Amgen (Etanercept), Immunex | Psoriatic Arthritis, Ankylosing Spondylitis | Dual-binding affinity profiling (Requires LTA vs. TNF-alpha panels) |
| Bispecific Antibody / Combos | Innovative Biotechs | Oncology (TLS Modulation), Autoimmune | Co-expression cell lines (Requires LTA/LTB Lentivirus) |